Outset Medical has raised $125 million in a Series E equity financing round that will help support the commercial expansion of the Tablo hemodialysis system in the U.S.
D1 Capital Partners led the round, with Fidelity Management and Research C., Partner Fund Management, Perceptive Advisors, and funds advised by T. Rowe Price Associates also participating.
The Tablo hemodialysis system is an all-in-one dialysis machine able to handle water purification and dialysate production. It can be used in a variety of different settings — a growing demand as the Trump administration pushes to move dialysis out of clinics and into home settings.
“With growing focus at the federal level on how to manage chronic kidney disease, which is increasingly prevalent, we believe Tablo is the only device with the potential to transform the delivery of dialysis,” Dan Sundheim, founder of D1 Capital Partners, said in a Feb. 4 news release.
San Jose, Calif.–based Outset Medical raised $132 million in its previous Series D round in 2018.
